CD274 and neoplasm: T-cell receptor clonality11, co-expression of other immunologic markers12, somatic mutational burden13, and PD-L1-expressing circulating tumor cells14 are also candidate biomarkers for the PD-L1 blockade therapy; however, these alternatives are lacking in conclusive evidence.